JP2021518366A5 - - Google Patents
Info
- Publication number
- JP2021518366A5 JP2021518366A5 JP2020549740A JP2020549740A JP2021518366A5 JP 2021518366 A5 JP2021518366 A5 JP 2021518366A5 JP 2020549740 A JP2020549740 A JP 2020549740A JP 2020549740 A JP2020549740 A JP 2020549740A JP 2021518366 A5 JP2021518366 A5 JP 2021518366A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- cell
- disorders
- compound according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023052481A JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841010656 | 2018-03-22 | ||
| IN201841010656 | 2018-03-22 | ||
| PCT/IB2019/052252 WO2019180631A1 (en) | 2018-03-22 | 2019-03-20 | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Division JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518366A JP2021518366A (ja) | 2021-08-02 |
| JP2021518366A5 true JP2021518366A5 (enExample) | 2022-03-29 |
| JP7254094B2 JP7254094B2 (ja) | 2023-04-07 |
Family
ID=67986029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549740A Active JP7254094B2 (ja) | 2018-03-22 | 2019-03-20 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023052481A Pending JP2023082088A (ja) | 2018-03-22 | 2023-03-28 | Ｐｒｍｔ５阻害剤としての置換イミダゾリジン－２－オン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11542275B2 (enExample) |
| EP (1) | EP3768671B1 (enExample) |
| JP (2) | JP7254094B2 (enExample) |
| KR (1) | KR102767362B1 (enExample) |
| CN (1) | CN112105609A (enExample) |
| AU (1) | AU2019237329B2 (enExample) |
| BR (1) | BR112020019111A2 (enExample) |
| CA (1) | CA3092770A1 (enExample) |
| CU (1) | CU24627B1 (enExample) |
| EA (1) | EA202092253A1 (enExample) |
| ES (1) | ES2982859T3 (enExample) |
| IL (1) | IL277518B2 (enExample) |
| MX (1) | MX2020009738A (enExample) |
| MY (1) | MY203159A (enExample) |
| PH (1) | PH12020551494A1 (enExample) |
| SG (1) | SG11202008526VA (enExample) |
| WO (1) | WO2019180631A1 (enExample) |
| ZA (1) | ZA202006137B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019180628A1 (en) * | 2018-03-22 | 2019-09-26 | Aurigene Discovery Technologies Limited | Imidazolidin-2-one compounds as prmt5 modulators |
| BR112020019111A2 (pt) * | 2018-03-22 | 2021-01-12 | Aurigene Discovery Technologies Limited | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| CN115232147B (zh) * | 2022-08-09 | 2023-10-13 | 南方科技大学 | 一种作为HIF-2α激动剂的杂环衍生物 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0960104B1 (en) * | 1996-04-17 | 2004-06-16 | Bristol-Myers Squibb Pharma Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US9029399B2 (en) * | 2011-04-28 | 2015-05-12 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| IN2012CH00067A (enExample) * | 2012-01-06 | 2017-08-04 | ||
| DK2935222T3 (en) * | 2012-12-21 | 2019-01-07 | Epizyme Inc | PRMT5 INHIBITORS AND APPLICATIONS THEREOF |
| US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
| JP2016511744A (ja) | 2012-12-21 | 2016-04-21 | エピザイム，インコーポレイティド | Ｐｒｍｔ５を阻害する方法 |
| JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| CA2899363A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2014108820A1 (en) | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CA2942833A1 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| TWI690521B (zh) * | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
| US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| EP3266784A1 (en) | 2016-06-08 | 2018-01-10 | Pierre Fabre Medicament | Protein arginine n-methyltransferases inhibitors and uses thereof |
| BR112020019111A2 (pt) * | 2018-03-22 | 2021-01-12 | Aurigene Discovery Technologies Limited | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 |
-
2019
- 2019-03-20 BR BR112020019111-6A patent/BR112020019111A2/pt unknown
- 2019-03-20 WO PCT/IB2019/052252 patent/WO2019180631A1/en not_active Ceased
- 2019-03-20 EA EA202092253A patent/EA202092253A1/ru unknown
- 2019-03-20 IL IL277518A patent/IL277518B2/en unknown
- 2019-03-20 CU CU2020000067A patent/CU24627B1/es unknown
- 2019-03-20 MY MYPI2020004843A patent/MY203159A/en unknown
- 2019-03-20 EP EP19771397.7A patent/EP3768671B1/en active Active
- 2019-03-20 JP JP2020549740A patent/JP7254094B2/ja active Active
- 2019-03-20 AU AU2019237329A patent/AU2019237329B2/en active Active
- 2019-03-20 SG SG11202008526VA patent/SG11202008526VA/en unknown
- 2019-03-20 MX MX2020009738A patent/MX2020009738A/es unknown
- 2019-03-20 ES ES19771397T patent/ES2982859T3/es active Active
- 2019-03-20 CA CA3092770A patent/CA3092770A1/en active Pending
- 2019-03-20 CN CN201980029962.0A patent/CN112105609A/zh active Pending
- 2019-03-20 US US16/982,800 patent/US11542275B2/en active Active
- 2019-03-20 KR KR1020207030078A patent/KR102767362B1/ko active Active
-
2020
- 2020-09-17 PH PH12020551494A patent/PH12020551494A1/en unknown
- 2020-10-02 ZA ZA2020/06137A patent/ZA202006137B/en unknown
-
2023
- 2023-03-28 JP JP2023052481A patent/JP2023082088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518366A5 (enExample) | ||
| JP2025023997A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| EP3632907B1 (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| ES2665073T3 (es) | Inhibidores de serina/treonina cinasa | |
| TWI805255B (zh) | 拮抗藥與免疫核查點阻礙藥而成之組合的用途 | |
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| JP2019535744A5 (enExample) | ||
| ES2908938T3 (es) | Nuevos derivados de benzamida como moduladores de PPAR-gamma | |
| ES2660215T3 (es) | Potenciador de efecto antitumoral que comprende un compuesto de imidazooxazina | |
| JP2013522292A5 (enExample) | ||
| RU2016107884A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| CA2736177A1 (en) | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases | |
| EP3632906B1 (en) | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | |
| JP2010538091A5 (enExample) | ||
| MX2010013699A (es) | Derivados de azacarbolinas, su preparacion y su uso terapeutico. | |
| CN110563703A (zh) | 基于crbn配体诱导parp-1降解的化合物及制备方法和应用 | |
| JP2017524013A5 (enExample) | ||
| JP2023533350A (ja) | 脳透過性ｂｔｋ又はｈｅｒ２阻害剤としての化合物およびその製造方法と応用 | |
| KR101739083B1 (ko) | 세포 증식성 질환 치료용 플래티넘 화합물, 그 제조방법 및 용도 | |
| JP2022519719A (ja) | プロスタグランジンｅ２（ｐｇｅ２）受容体調節薬としての新規なｎ－ベンジル－２－フェノキシベンズアミド誘導体 | |
| WO2021218319A1 (zh) | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 | |
| CN103450133A (zh) | 具有抗肿瘤活性的东莨菪素衍生物、其制备方法及用途 | |
| CN104292233B (zh) | 一种吡唑并[1,5-a]嘧啶衍生物及其抗肿瘤用途 | |
| Yang et al. | Synthesis, crystal structure, and in vitro antitumor activities of copper (II) complexes containing tetradentate pyridine-based ligands | |
| Pandey et al. | In vitro and in vivo studies on antitumor potential of Ni (II) and Pd (II) complexes based on a series of thiourea-based ligands |